Genome editing technologies promise therapeutic advances for genetic diseases. We discuss the ethical and societal issues raised by these technologies, including their use in preclinical research, their potential to address mutations in somatic cells, and their potential to make germ line alterations that may be passed to subsequent generations. We call for a proportionate response from health leaders based on a realistic assessment of benefits, risks, and timelines for clinical translation.
History
Publication title
Healthcare Management Forum
Volume
30
Pagination
159-163
ISSN
0840-4704
Department/School
Faculty of Law
Publisher
Sage Publications, Inc.
Place of publication
United States
Rights statement
Copyright 2017 The Canadian College of Health Leaders